Mitochondrial oxidative damage in aging and Alzheimer's disease: Implications for mitochondrially targeted antioxidant therapeutics

Journal of Biomedicine and Biotechnology

Volumn 2006, Issue , 2006, Pages

  Reddy, P Hemachandra ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [4 [[(1,1 DIMETHYLETHYL)OXIDOIMINO]METHYL]PHENOXY]BUTYL]TRIPHENYLPHOSPHONIUM BROMIDE; ALPHA PHENYL N TERT BUTYL NITRONE DERIVATIVE; ALPHA TOCOPHEROL DERIVATIVE; ALZHEIMER DISEASE VACCINE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BUTYLCHOLINESTERASE INHIBITOR; CHOLINESTERASE INHIBITOR; CYMSERINE DERIVATIVE; DONEPEZIL; FREE RADICAL; GALANTAMINE; MITOCHONDRIAL ANTIOXIDANT; MITOPBN; MITOPEROXIDASE; MITOQ; MITOQUINONE; MITOVITE; N [4 (OCTA O ACETYLLACTOBIONAMIDOMETHYLENE)BENZYLIDENE] N [1,1 DIMETHYL 2 (N OCTANOYL)AMIDO]ETHYLAMINE N OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN INHIBITOR; QUINOLINE DERIVATIVE; RIVASTIGMINE; SS 02; SS 02 TETRAPEPTIDE; SS 19; SS 19 TETRAPEPTIDE; SS 20; SS 20 TETRAPEPTIDE; SS 31; SS 31 TETRAPEPTIDE; SS TETRAPEPTIDE; TACRINE; TAU PROTEIN; TETRAPEPTIDE; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGED; AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MITOCHONDRIAL TOXICITY; OXIDATIVE STRESS; PROTEIN HYPERPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPTIC FAILURE; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 33646349444     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/JBB/2006/31372     Document Type: Review

References (125)

1. D J Selkoe Alzheimer's disease: genes, proteins, and therapy. Physiological Reviews 81 2001 2 741 766 11274343
2. M P Mattson mattsonm@grc.nia.nih.gov Pathways towards and away from Alzheimer's disease. Nature 430 2004 7000 631 639 15295589
3. P H Reddy S McWeeney Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiology of Aging 2005 September 9; [Epub ahead of print] 16157420
4. T S Anekonda P H Reddy Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Research. Brain Research Reviews 50 2005 2 361 376 16263176
5. P H Reddy M F Beal Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Research. Brain Research Reviews 49 2005 3 618 632 Epub 2005 April 19 16269322
6. P H Reddy Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. Journal of Neurochemistry 96 2006 1 1 13 16305625
7. X Zhu Xiongwei.Zhu@case.edu H G Lee G Casadesus Oxidative imbalance in Alzheimer's disease. Molecular Neurobiology 31 2005 1-3 205 217 15953822
8. R H Swerdlow rhs7e@virginia.edu S M Khan A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Medical Hypotheses 63 2004 1 8 20 15193340
9. P G Sullivan PatSull@uky.edu M R Brown Mitochondrial aging and dysfunction in Alzheimer's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 29 2005 3 407 410 15795049
10. J Raber raberj@ohsu.edu Y Huang J W Ashford ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiology of Aging 25 2004 5 641 650 15172743
11. J Raber Androgens, apoE, and Alzheimer's disease. Science of Aging Knowledge Environment 2004 2004 11 re2 15028864
12. S M de la Monte Suzanne_DeLaMonte_MD@Brown.edu J R Wands Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. Journal of Alzheimer's Disease 7 2005 1 45 61 15750214
13. M Kitazawa T R Yamasaki F M LaFerla laferla@uci.edu Microglia as a Potential Bridge between the Amyloid {beta}-Peptide and Tau. Annals of the New York Academy of Sciences 1035 2004 85 103 15681802
14. S Oddo L Billings J P Kesslak D H Cribbs F M LaFerla Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 2004 3 321 332 15294141
15. S Oddo A Caccamo L Tran Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. The Journal of Biological Chemistry 281 2006 3 1599 1604 November 10; [Epub ahead of print] 16282321
16. S Oddo A Caccamo J D Shepherd Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 2003 3 409 421 12895417
17. D Morgan dmorgan@hsc.usf.edu M N Gordon J Tan D Wilcock A M Rojiani Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. Journal of Neuropathology and Experimental Neurology 64 2005 9 743 753 16141783
18. J W Lustbader M Cirilli C Lin ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 2004 5669 448 452 15087549
19. P J Crouch R Blake J A Duce Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. Journal of Neuroscience 25 2005 3 672 679
20. A Nordberg E Hellstrom-Lindahl M Lee Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). Journal of Neurochemistry 81 2002 3 655 658 12065674
21. P H Reddy S McWeeney B S Park Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Human Molecular Genetics 13 2004 12 1225 1240 Epub 2004 April 28 15115763
22. P H Reddy G Mani B S Park Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. Journal of Alzheimer's Disease 7 2005 2 103 117 discussion 173-80 15851848
23. M Manczak B S Park Y Jung P H Reddy Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Medicine 5 2004 2 147 162 15075441
24. K Hirai G Aliev A Nunomura Mitochondrial abnormalities in Alzheimer's disease. Journal of Neuroscience 21 2001 9 3017 3023 11312286
25. D Schenk dschenk@elanpharma.com R Barbour W Dunn Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 1999 6740 173 177 10408445
26. D Morgan D M Diamond P E Gottschall A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 2000 6815 982 985 11140686
27. R B DeMattos K R Bales D J Cummins J C Dodart S M Paul D M Holtzman holtzman@neuro.wustl.edu Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 98 2001 15 8850 8855 11438712
28. D S Gelinas K DaSilva D Fenili P St George-Hyslop J McLaurin j.mclaurin@utoronto.ca Immunotherapy for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 101 2004 suppl 2 14657 14662 Epub 2004 August 5 15297619
29. P L McGeer E G McGeer The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research. Brain Research Reviews 21 1995 2 195 218 8866675
30. L J Launer Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next? The Journal of the American Medical Association 289 2003 21 2865 2867 12783919
31. L Gasparini E Ongini ongini@nicox.it G Wenk Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action. Journal of Neurochemistry 91 2004 3 521 536 15485484
32. L Gasparini E Ongini D Wilcock D Morgan Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Research. Brain Research Reviews 48 2005 2 400 408 15850679
33. H Nakashima T Ishihara takeshiishihara@yahoo.com O Yokota Effects of alpha-tocopherol on an animal model of tauopathies. Free Radical Biology & Medicine 37 2004 2 176 186 15203189
34. V Conte K Uryu S Fujimoto Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry 90 2004 3 758 764 15255955
35. S Sung Y Yao K Uryu Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. The FASEB Journal 18 2004 2 323 325 14656990
36. E Matsubara T Bryant-Thomas J Pacheco Quinto Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Journal of Neurochemistry 85 2003 5 1101 1108 12753069
37. R W Stackman stackman@ohsu.edu F Eckenstein B Frei D Kulhanek J Nowlin J F Quinn Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology 184 2003 1 510 520 14637120
38. F Yang G P Lim A N Begum Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. The Journal of Biological Chemistry 280 2005 7 5892 5901 15590663
39. M C Morris L A Beckett P A Scherr Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Disease and Associated Disorders 12 1998 3 121 126 9772012
40. M C Morris D A Evans J L Bienias Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. The Journal of the American Medical Association 287 2002 24 3230 3237 12076219
41. M C Morris martha_c_morris@rush.edu D A Evans C C Tangney Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. The American Journal of Clinical Nutrition 81 2005 2 508 514 15699242
42. M Grundman mgrundman@ucsd.edu R C Petersen S H Ferris Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology 61 2004 1 59 66 14732621
43. P P Zandi pzandi@jhsph.edu J C Anthony A S Khachaturian Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Archives of Neurology 61 2004 1 82 88 14732624
44. N A Clarke englishmemory@hotmail.com P T Francis paul.francis@kcl.ac.uk Cholinergic and glutamatergic drugs in Alzheimer's disease therapy. Expert Review of Neurotherapeutics 5 2005 5 671 682 16162091
45. M Racchi racchi@unipv.it M Mazzucchelli S C Lenzken E Porrello C Lanni S Govoni Role of acetylcholinesterase inhibitors in the regulation of amyloid beta precursor protein (AbetaPP) metabolism. Chemico-Biological Interactions 157-158 2005 335 338 November 16; [Epub ahead of print] 16297899
46. H Kaduszkiewicz Kaduszkiewiczkaduszki@uke.uni-hamburg.de T Zimmermann H P Beck-Bornholdt H van den Bussche Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. British Medical Journal 331 2005 7512 321 327 16081444
47. N H Greig greign@grc.nia.nih.gov T Utsuki D K Ingram Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proceedings of the National Academy of Sciences of the United States of America 102 2005 47 17213 17218 16275899
48. J M Ellis IMdocjay@aol.com Cholinesterase inhibitors in the treatment of dementia. The Journal of the American Osteopathic Association 105 2005 3 145 158 15863734
49. M Zimmermann Martina.Zimmermann@unimi.it B Borroni F Cattabeni A Padovani M Di Luca Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiology of Disease 19 2005 1-2 237 242 15837579
50. D G Wilkinson david.wilkinson@wht.nhs.uk P T Francis E Schwam J Payne-Parrish Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs & Aging 21 2004 7 453 478 15132713
51. D K Lahiri dlahiri@iupui.edu J T Rogers N H Greig K Sambamurti Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Current Pharmaceutical Design 10 2004 25 3111 3119 15544501
52. X Zhu A K Raina G Perry M A Smith Mark.Smith@case.ed Alzheimer's disease: the two-hit hypothesis. Lancet Neurology 3 2004 4 219 226 15039034
53. K Herrup kxh26@case.edu R Neve S L Ackerman A Copani Divide and die: cell cycle events as triggers of nerve cell death. The Journal of Neuroscience 24 2004 42 9232 9239 15496657
54. R L Neve D L McPhie The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacology & Therapeutics 2005 November 7; [Epub ahead of print] 16274748
55. M X Tang D Jacobs Y Stern Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348 1996 9025 429 432 8709781
56. M W Marlatt K M Webber P I Moreira Therapeutic opportunities in Alzheimer disease: one for all or all for one? Current Medicinal Chemistry 12 2005 10 1137 1147 15892629
57. G Casadesus X Zhu C S Atwood Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Current Drug Targets. CNS and Neurological Disorders 3 2004 4 281 285 15379604
58. R P Koldamova radak@pitt.edu I M Lefterov iliyal@pitt.edu M Staufenbiel The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. The Journal of Biological Chemistry 280 2005 6 4079 4088 15557325
59. E Ognibene S Middei S Daniele Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. Behavioural Brain Research 156 2005 2 225 232 15582108
60. D M Walsh M Townsend M B Podlisny Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. The Journal of Neuroscience 25 2005 10 2455 2462 15758153
61. N Abbas I Bednar E Mix Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. Journal of Neuroimmunology 126 2002 1-2 50 57 12020956
62. R Tehranian S Andell-Jonsson S M Beni Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. Journal of Neurotrauma 19 2002 8 939 951 12225654
63. P Kasa kp@comser.szote.u-szeged.hu Z Rakonczay K Gulya The cholinergic system in Alzheimer's disease. Progress in Neurobiology 52 1997 6 511 535 9316159
64. M A Lovell W D Ehmann S M Butler W R Markesbery Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45 1995 8 1594 1601 7644059
65. W R Markesbery wmarkesbery@aging.coa.uky.edu J M Carney Oxidative alterations in Alzheimer's disease. Brain Pathology 9 1999 1 133 146 9989456
66. M A Pappolla R A Omar K S Kim N K Robakis Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. The American Journal of Pathology 140 1992 3 621 628 1372157 Erratum in: The American Journal of Pathology. 1996;149(5):1770
67. M A Pappolla mpappoll@usamail.usouthal.edu Y J Chyan B Poeggeler Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin. Journal of Pineal Research 27 1999 4 226 229 10551770
68. P Bozner V Grishko S P LeDoux G L Wilson Y C Chyan M A Pappolla The amyloid beta protein induces oxidative damage of mitochondrial DNA. Journal of Neuropathology and Experimental Neurology 56 1997 12 1356 1362 9413284
69. L Lyras R H Perry E K Perry Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. Journal of Neurochemistry 71 1998 1 302 312 9648879
70. D A Butterfield dabcns@pop.uky.edu J Drake C Pocernich A Castegna Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends in Molecular Medicine 7 2001 12 548 554 11733217
71. L Meda M A Cassatella G I Szendrei Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374 1995 6523 647 650 7715705
72. L Qin qin1@niehs.nih.gov Y Liu C Cooper B Liu B Wilson J S Hong Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. Journal of Neurochemistry 83 2002 4 973 983 12421370
73. C W Olanow An introduction to the free radical hypothesis in Parkinson's disease. Annals of Neurology 32 1992 suppl S2 S9 1510376
74. S Varadarajan S Yatin M Aksenova D A Butterfield Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. Journal of Structural Biology 130 2000 2-3 184 208 10940225
75. M A Smith R K Kutty P L Richey Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. The American Journal of Pathology 145 1994 1 42 47 8030754
76. M A Smith G Perry P L Richey Oxidative damage in Alzheimer's. Nature 382 1996 6587 120 121 8700201
77. L M Sayre D A Zelasko P L Harris G Perry R G Salomon M A Smith 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Journal of Neurochemistry 68 1997 5 2092 2097 9109537
78. P F Good P Werner A Hsu C W Olanow D P Perl Evidence of neuronal oxidative damage in Alzheimer's disease. The American Journal of Pathology 149 1996 1 21 28 8686745
79. C Behl Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Sub-Cellular Biochemistry 38 2005 65 78 15709473
80. E Cadenas cadenas@hsc.usc.edu K J Davies Mitochondrial free radical generation, oxidative stress, and aging. Free Radical Biology & Medicine 29 2000 3-4 222 230 11035250
81. E Cadenas Mitochondrial free radical production and cell signaling. Molecular Aspects of Medicine 25 2004 1-2 17 26 15051313
82. J F Turrens Mitochondrial formation of reactive oxygen species. The Journal of Physiology 552 2003 pt 2 335 344 14561818
83. F L Muller mullerf@uthscsa.edu Y Liu H Van Remmen Complex III releases superoxide to both sides of the inner mitochondrial membrane. The Journal of Biological Chemistry 279 2004 47 49064 49073 15317809
84. A A Starkov G Fiskum C Chinopoulos Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. The Journal of Neuroscience 24 2004 36 7779 7788 15356189
85. D C Wallace dwallace@gmm.gen.emory.edu Mitochondrial diseases in man and mouse. Science 283 1999 5407 1482 1488 10066162
86. S S Sheu sheyshing_sheu@urmc.Rochester.edu D Nauduri M W Anders Targeting antioxidants to mitochondria: a new therapeutic direction. Biochimica et Biophysica Acta 1762 2006 2 256 265 16352423
87. M F Beal fbeal@med.cornell.edu Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology 58 2005 4 495 505 16178023
88. R Jr Dawson M F Beal S C Bondy D A Di Monte G E Isom Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicology and Applied Pharmacology 134 1995 1 1 17 7676443
89. J R Richardson Y Quan T B Sherer J T Greenamyre G W Miller gary.miller@emory.edu Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences 88 2005 1 193 201 16141438
90. S McCarthy M Somayajulu M Sikorska H Borowy-Borowski S Pandey spandey@uwindsor.ca Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicology and Applied Pharmacology 201 2004 1 21 31 15519605
91. M R Brown J W Geddes jgeddes@uky.edu P G Sullivan Brain region-specific, age-related, alterations in mitochondrial responses to elevated calcium. Journal of Bioenergetics and Biomembranes 36 2004 4 401 406 15377879
92. A Y Abramov M R Duchen The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 360 2005 1464 2309 2314 16321801
93. P G Sullivan A G Rabchevsky J N Keller Intrinsic differences in brain and spinal cord mitochondria: implication for therapeutic interventions. The Journal of Comparative Neurology 474 2004 4 524 534 15174070
94. S M Cardoso S Santos R H Swerdlow C R Oliveira Functional mitochondria are required for amyloid beta-mediated neurotoxicity. The FASEB Journal 15 2001 8 1439 1441 11387250
95. H K Anandatheerthavarada G Biswas M A Robin N G Avadhani narayan@vet.upenn.edu Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. The Journal of Cell Biology 161 2003 1 41 54 12695498
96. S Melov smelov@buckinstitute.org N Wolf D Strozyk S R Doctrow A I Bush bush@helix.mgh.harvard.edu Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radical Biology & Medicine 38 2005 2 258 261 15607908
97. Z J Zhang zzhang1@usuhs.mil Y H Qian H T Hu J Yang G D Yang The herbal medicine Dipsacus asper wall extract reduces the cognitive deficits and overexpression of beta-amyloid protein induced by aluminum exposure. Life Sciences 73 2003 19 2443 2454 12954453
98. A Krzepilko A Swiecilo J Wawryn Ascorbate restores lifespan of superoxide-dismutase deficient yeast. Free Radical Research 38 2004 9 1019 1024 15621721
99. H Ruan X D Tang M L Chen High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proceedings of the National Academy of Sciences of the United States of America 99 2002 5 2748 2753 11867705 Epub 2002 February 26
100. T Magwere M West K Riyahi M P Murphy R A Smith L Partridge l.partridge@ucl.ac.uk The effects of exogenous antioxidants on lifespan and oxidative stress resistance in Drosophila melanogaster. Mechanisms of Ageing and Development 127 2006 4 356 370 16442589 [Epub ahead of print]
101. S E Schriner N J Linford G M Martin Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308 2005 5730 1909 1911 15879174
102. G F Kelso C M Porteous C V Coulter Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. The Journal of Biological Chemistry 276 2001 7 4588 4596 11092892
103. R A Smith C M Porteous C V Coulter M P Murphy murphy@sanger.otago.ac.nz Selective targeting of an antioxidant to mitochondria. European Journal of Biochemistry 263 1999 3 709 716 10469134
104. M P Murphy K S Echtay F H Blaikie Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. The Journal of Biological Chemistry 278 2003 49 48534 48545 12972420
105. K Zhao G M Zhao D Wu Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. The Journal of Biological Chemistry 279 2004 33 34682 34690 15178689 Epub 2004 June 2
106. K Zhao G Luo S Giannelli H H Szeto hhszeto@med.cornell.edu Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochemical Pharmacology 70 2005 12 1796 1806 16216225 Epub 2005 October 10
107. M P Murphy R A Smith Drug delivery to mitochondria: the key to mitochondrial medicine. Advanced Drug Delivery Reviews 41 2000 2 235 250 10699318
108. M P Murphy Selective targeting of bioactive compounds to mitochondria. Trends in Biotechnology 15 1997 8 326 330 9263481
109. F L Crane Hydroquinone dehydrogenases. Annual Review of Biochemistry 46 1977 439 469 197879
110. V E Kagan E A Serbinova D A Stoyanovsky S Khwaja L Packer Assay of ubiquinones and ubiquinols as antioxidants. Methods in Enzymology 234 1994 343 354 7808306
111. J J Maguire D S Wilson L Packer Mitochondrial electron transport-linked tocopheroxyl radical reduction. The Journal of Biological Chemistry 264 1989 36 21462 21465 2557330
112. L Ernster P Forsmark K Nordenbrand The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles. BioFactors 3 1992 4 241 248 1605833
113. K U Ingold V W Bowry R Stocker C Walling Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 90 1993 1 45 49 8419943
114. P M Hwang F Bunz J Yu Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nature Medicine 7 2001 10 1111 1117 11590433
115. M L Jauslin T Meier R A Smith M P Murphy Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. The FASEB Journal 17 2003 13 1972 1974 12923074
116. B Bedogni G Pani R Colavitti Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival. The Journal of Biological Chemistry 278 2003 19 16510 16519 12609977
117. A Dhanasekaran S Kotamraju S V Kalivendi Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. The Journal of Biological Chemistry 279 2004 36 37575 37587 15220329
118. R A Smith C M Porteous A M Gane M P Murphy Delivery of bioactive molecules to mitochondria in vivo. Proceedings of the National Academy of Sciences of the United States of America 100 2003 9 5407 5412 12697897
119. V J Adlam J C Harrison C M Porteous Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. The FASEB Journal 19 2005 9 1088 1095 15985532
120. G Hughes M P Murphy E C Ledgerwood liz.ledgerwood@stonebow.otago.ac.nz Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappaB to modulate tumour necrosis factor-induced apoptosis: evidence from mitochondria-targeted antioxidants. The Biochemical Journal 389 2005 pt 1 83 89 15727562
121. D Han F Antunes R Canali D Rettori E Cadenas Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. The Journal of Biological Chemistry 278 2003 8 5557 5563 12482755
122. B Poeggeler bpoegge@gwdg.de G {Durand} A Polidori Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitrone LPBNAH acting as a highly potent antioxidant agent. Journal of Neurochemistry 95 2005 4 962 973 16135084
123. J S Wright D J Capenter D J McKay K U Ingold Theortical calculation of substituent effects on the O-H bond strength of phenolic antioxidants related to vitamin E. Journal of the American Chemical Society 1997 4245 4252
124. K Zhao G Luo G M Zhao P W Schiller H H Szeto Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. The Journal of Pharmacology and Experimental Therapeutics 304 2003 1 425 432 12490619
125. G M Zhao X Qian P W Schiller H H Szeto Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. The Journal of Pharmacology and Experimental Therapeutics 307 2003 3 947 954 14534366